Skip to main content
. Author manuscript; available in PMC: 2016 Sep 1.
Published in final edited form as: Biol Blood Marrow Transplant. 2015 May 8;21(9):1589–1596. doi: 10.1016/j.bbmt.2015.05.002

Table 2.

Multivariate analysis of recipient KIR Ligands for AML only

Recipient KIR Ligands All present ≥ 1 absent
N Reference N HR (95% CI) P-value
Overall survivala 217 1.00 395 1.04 (0.85–1.28) 0.69
DFSb 217 1.00 395 0.93 (0.75–1.15) 0.49
TRMc 213 1.00 390 1.43 (1.01–2.01) 0.04
Relapsed 215 1.00 394 0.81 (0.62–1.05) 0.11
aGVHD II–IVe 217 1.00 392 1.22 (0.97–1.53) 0.09
aGVHD III–IVf 217 1.00 393 1.63 (1.16–2.28) 0.005
cGVHDg 208 1.00 387 1.07 (0.84–1.37) 0.59
a

Adjusted for disease stage, donor/recipient CMV matching, GVHD prophylaxis, recipient race/ethnicity and stratified by graft type.

b

Adjusted for disease stage and stratified by graft type, donor/recipient CMV matching and Karnofsky score.

c

Adjusted for recipient race/ethnicity, donor/recipient sex matching, conditioning regimen, GVHD prophylaxis, time from diagnosis to transplant and stratified by graft type.

d

Adjusted for disease stage and time from diagnosis to transplant and stratified by conditioning regimen and Karnofsky score.

e

Adjusted for graft type, GVHD prophylaxis, recipient race and stratified by use of CAMPATH.

f

Adjusted for HLA matching, recipient race/ethnicity, GVHD prophylaxis and Karnofsky score.

g

Adjusted for in-vivo T-cell depletion, conditioning regimen, GVHD prophylaxis and stratified by recipient CMV status.